Selling, General, and Administrative Costs: Alkermes plc vs Wave Life Sciences Ltd.

A Tale of Two Biotechs: Alkermes plc vs. Wave Life Sciences Ltd.

In the ever-evolving landscape of biotechnology, understanding financial health is crucial. Over the past decade, Alkermes plc and Wave Life Sciences Ltd. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A costs surged by approximately 245%, reflecting its aggressive expansion and operational scaling. In contrast, Wave Life Sciences Ltd. experienced a more modest increase of around 1,610%, albeit from a much smaller base, indicating its strategic investments in growth and innovation.

Key Insights

• Alkermes plc: By 2023, SG&A expenses reached nearly 690 million, highlighting its commitment to maintaining a competitive edge.
• Wave Life Sciences Ltd.: Despite a smaller scale, its expenses grew significantly, reaching over 51 million, showcasing its dedication to research and development.

These trends underscore the dynamic strategies employed by these biotech firms in a competitive market.